Radiometals possess an exceptional breadth of decay properties and have been applied to
medicine with great success for several decades. The majority of current clinical use …

Radiometals comprise many useful radioactive isotopes of various metallic elements. When
properly harnessed, these have valuable emission properties that can be used for …

Several monoclonal antibodies are now approved for cancer therapy, such as rituximab, an
anti-CD20 monoclonal antibody for the treatment of B-cell non-Hodgkin's lymphoma …

Cyclams are 14-membered tetraamine macrocycles which bind strongly to a wide range of
metal ions. Medical interest has centred on clinical trials of a bicyclam for the treatment of …

Immuno-PET as a scouting procedure before radioimmunotherapy (RIT) aims at confirming
tumor targeting and accurately estimating radiation dose delivery to both tumor and normal …

The use of “non-standard” metallic radionuclides continues to be an expanding field of
investigation. Radiolabeling small molecules, peptides, proteins, and up to nano-particles …

We report a nonadentate bispidine (3, 7-diazabicyclo [3.3. 1] nonane) that unveils the
potential to bind theranostically relevant radionuclides, including indium-111, lutetium-177 …

Monoclonal antibodies have become a viable strategy for the delivery of therapeutic, particle
emitting radionuclides specifically to tumor cells to either augment anti-tumor action of the …

Recombinant antibodies currently represent over 30% of biopharmaceuticals in clinical
trials, highlighted by the recent Food and Drug Administration (FDA) approvals of …

Despite the advances in molecular biology and biochemistry, the prognosis of patients
suffering from tumor diseases remains poor. The limited therapeutic success can be …